Urinary paraben mixtures were tied to luteinizing hormone, not to FSH or prolactin
Parabens sit in a familiar place in daily life: cosmetics, personal care products, and other consumer goods that many women encounter repeatedly. Their appeal comes from antimicrobial preservation, but their biological footprint is harder to dismiss when exposure is measured against reproductive hormones. In this cross-sectional study of 84 women of reproductive age at Imam Reza Hospital in Kermanshah, Iran, urinary parabens were quantified alongside serum reproductive markers, and the most consistent signal emerged around luteinizing hormone.
MePB was the most abundant urinary paraben, yet abundance did not translate neatly into the largest biological effect. BuPB contributed 65.1% of cumulative estrogenic activity, a reminder that endocrine relevance depends on potency as much as concentration. In mixtures, weaker signals can behave like a chorus rather than a solo line: the aggregate exposure may be modest, but the endocrine system still reads the blend.
The pattern centered on LH, with opposite-direction contributions from individual parabens
Urinary concentrations of methylparaben, ethylparaben, propylparaben, and butylparaben were measured by GC-MS and adjusted for specific gravity. Serum FSH, LH, and prolactin were assessed by ELISA. Multivariable linear regression and exploratory relative-weight analysis were used to examine mixture-based associations, and the only statistically significant associations appeared in the LH model, where the effective sample size was 35.
PrPB carried the largest positive contribution to LH at 45% with a p value of 0.021. EtPB followed at 24% with a p value of 0.032. On the inverse side, BuPB accounted for 23% with a p value of 0.033, and MePB contributed 8% with a p value of 0.037. No significant associations emerged for FSH or prolactin. The biology here is plausible even if the directionality is complex: endocrine disruptors can exert modest agonist or antagonistic effects depending on tissue, dose, timing, and mixture context, and the hypothalamic-pituitary-gonadal axis can respond to small shifts in signal strength.
This is the kind of result that resists a simple one-chemical, one-hormone story. LH is especially sensitive to upstream endocrine perturbation because it sits at the center of ovulatory signaling, steroidogenesis, and cycle regulation. Even subtle shifts in LH-related signaling may matter more than a laboratory result suggests at first glance, particularly in women whose reproductive function depends on tightly timed hormonal pulses.
Estrogenic activity concentrated in BuPB even when overall measured risk stayed low
The exposure profile deserves attention on its own terms. Although MePB was the most abundant compound, BuPB dominated the cumulative estrogenic burden. That mismatch is important because toxicology does not move in lockstep with raw concentration; receptor binding, metabolic persistence, and bioactivity all shape what the endocrine system actually experiences.
Risk assessment did not point to a high non-carcinogenic hazard. Hazard quotients stayed below 1, and the 95th percentile hazard index reached 0.0998. Monte Carlo simulations also supported negligible non-carcinogenic risk. Those findings limit any claim of overt toxic burden at the measured exposure levels, but they do not erase the hormonal signal. Endocrine effects often appear below thresholds used for conventional toxicity screening, especially when the endpoint is regulatory disruption rather than frank injury.
Why a low hazard index does not end the reproductive question
The study’s design fits environmental reproductive epidemiology rather than causal proof. It is cross-sectional, so hormone levels and exposure were captured at one point in time. That matters because reproductive hormones vary across the menstrual cycle, and urinary biomarkers reflect recent exposure rather than a long historical record. Sample size was also modest, and the LH model involved only 35 participants, which makes confidence in the exact weight assigned to each paraben more tentative than the p values alone might suggest.
Still, the findings fit a known biological concern: parabens can behave as endocrine-active compounds, and women of reproductive age represent a group in whom even mild interference with hormonal regulation may be clinically relevant. The signal did not show up in FSH or prolactin, which argues against a broad, nonspecific pituitary effect in this dataset. The association clustered around LH, pointing to a narrower endocrine pattern rather than a generalized suppression of pituitary function.
What clinicians and researchers should take from the mixture signal
For clinicians, the practical takeaway is not that everyday paraben exposure has been proven to damage fertility. The data do not justify that leap. The stronger message is that common environmental mixtures can register biologically at exposures that still fall well below conventional non-carcinogenic risk thresholds. That makes routine risk framing more complicated in reproductive medicine, where timing, ovulatory cycling, and endocrine sensitivity can shape outcomes long before a toxicology threshold is crossed.
For researchers, the next step is clear in method even if it remains open in result: larger cohorts, repeated hormone sampling across the menstrual cycle, and exposure models that account for mixture behavior over time. A single urine sample is useful, but it is only a snapshot. A single hormone draw is even more fragile when the endpoint is cyclic and pulsatile.
The study closes with a familiar environmental health tension. Measured hazard stayed low, yet hormonal associations still appeared, and they appeared in the endocrine axis most relevant to ovulation. That combination does not prove harm, but it does justify closer surveillance of paraben mixtures in women of reproductive age, especially when cumulative exposure is likely to come from multiple consumer products rather than a single source.